Senior Vice President of Technical Operations
Christopher J. Morrison serves as Senior Vice President of Technical Operations at Myrtelle, where he oversees all internal and external vector manufacturing, process development, supply chain, analytical development and quality control activities. He joined the company in 2021, bringing more than 15 years of pharmaceutical industry and academic bioprocessing experience. Most recently Chris was Vice President of Technology Development at Adverum Biotechnologies where he oversaw all process development and MS&T activities from research to late-stage clinical manufacturing. Prior to Adverum, Chris has held various CMC related positions of increasing responsibility in a number of viral gene therapy startups, including ApicBio, Gemini Therapeutics, Voyager Therapeutics and Dimension Therapeutics (now part of Ultragenyx). Having worked on over 20 different rAAV therapeutic projects to date, Chris has led the development and implementation of both early and late-stage manufacturing processes for numerous products of assorted serotype and genomic construct produced by Sf9-Baculovirus, HeLa-Adenovirus or HEK293 transient transfection-based production systems. Chris began his industrial career at Pfizer, working on the downstream purification processes for various CHO based therapeutics. He holds a B.S. in Chemical Engineering from the University of Wisconsin – Madison and a Ph.D. in Chemical and Biological Engineering from Rensselaer Polytechnic Institute.
Chris’ drive coming to work every day is to help establish and drive the maturity of the viral gene therapeutics field by setting a high bar of CMC excellence, ultimately leading to more cutting-edge therapies being reliably delivered to waiting patients in a safe and effective manner.